The cGAS-STING pathway and autophagy form a bidirectional regulatory network that is central to neurodegenerative disease pathogenesis. While the cGAS-STING pathway detects cytosolic DNA and triggers type I interferon responses, autophagy serves as both a downstream effector and a negative regulator of this pathway[1]. This crosstalk creates feedback loops that either amplify neuroinflammation or provide neuroprotection, depending on the cellular context and disease stage[2].
The relationship is particularly important in Alzheimer's disease and Parkinson's disease where mitochondrial dysfunction, DNA damage accumulation, and cellular senescence converge to activate cGAS-STING while simultaneously impairing autophagic flux[3].
Upon activation by cGAMP, STING undergoes autophagosomal degradation through a mechanism that serves as a built-in negative feedback loop[4]. This process involves:
This autophagic degradation of STING limits the duration and intensity of type I interferon responses, preventing excessive inflammation[1:1]. In neurons, however, this feedback mechanism is often impaired due to lysosomal dysfunction, leading to sustained STING activation.
The STING autophagy degradation pathway has been leveraged for therapeutic purposes:
The type I interferon response activated by cGAS-STING feeds back to suppress autophagy initiation through mTOR activation[7]:
This creates a vicious cycle in neurodegenerative disease: cGAS-STING activation suppresses autophagy, leading to accumulation of protein aggregates and damaged mitochondria, which further activates cGAS-STING[8].
p62-mediated selective autophagy plays a critical role in clearing cytosolic DNA to prevent chronic cGAS activation[9]:
In Alzheimer's disease, tau pathology disrupts this pathway by interfering with p62 recruitment and autophagosome-lysosome fusion[10].
Mitochondrial DNA (mtDNA) is the major source of cytosolic DNA that activates cGAS-STING in neurons and glia[1:2]. Under normal conditions, mtDNA is contained within the mitochondrial matrix. In neurodegeneration, multiple mechanisms promote mtDNA release:
| Mechanism | Disease Context | Effect on cGAS-STING |
|---|---|---|
| Mitochondrial permeability transition pore (mPTP) opening | AD, PD | Cytosolic mtDNA leakage |
| BAX/BAK pore formation | PD (PINK1/Parkin mutations) | mtDNA release through outer membrane pores |
| VDAC oligomerization | Aging, AD | mtDNA passage through voltage-dependent anion channels |
| Mitochondrial matrix rupture | Oxidative stress | Release of mtDNA copies into cytosol |
| Mitochondrial dynamics imbalance | PD (LRRK2 mutations) | Fragmented mitochondria with compromised membrane integrity |
The PINK1-Parkin mitophagy pathway has a direct relationship with cGAS-STING[11]:
Research using PINK1 knockout mice demonstrates elevated cytosolic mtDNA, hyperactivated cGAS-STING signaling, and increased neuroinflammation compared to wild-type controls[11:1].
LRRK2 mutations are the most common genetic cause of familial Parkinson's disease. LRRK2 regulates mitochondrial dynamics through:
The LRRK2-mitochondrial dysfunction-cGAS-STING axis provides a mechanistic link between the most common PD gene mutation and neuroinflammation.
Microglia utilize cGAS-STING signaling to detect pathogens and cellular damage, but chronic activation drives pathological pro-inflammatory polarization[12]:
Enhancing microglial autophagy represents a promising therapeutic strategy to break the inflammatory cycle[13]:
Trehalose is a natural disaccharide that induces autophagy through multiple mechanisms, making it a candidate for cGAS-STING-related neurodegeneration:
Rapamycin (mTOR inhibitor) induces autophagy but has a complex relationship with cGAS-STING:
Combination strategies targeting both cGAS-STING inhibition and autophagy enhancement show promise[14]:
In Alzheimer's disease, cGAS-STING-autophagy crosstalk is shaped by amyloid-beta and tau pathology[3:1]:
Key targets for AD intervention: cGAS inhibitors (RU.521), STING antagonists (H-151), autophagy enhancers (trehalose, Tat-beclin1).
In Parkinson's disease, mitochondrial dysfunction is the central driver of cGAS-STING activation[16]:
In ALS, TDP-43 pathology and C9orf72 repeat expansions intersect with cGAS-STING-autophagy[2:1]:
| Target | Agent/Approach | Mechanism | Disease Focus |
|---|---|---|---|
| cGAS inhibition | RU.521, G150 | Blocks cGAMP synthesis | AD, ALS |
| STING antagonism | H-151, C-176 | Blocks TBK1/IRF3 activation | PD, AD |
| Autophagy enhancement | Trehalose, rapamycin | mTOR-independent activation | PD, AD |
| Mitophagy induction | PINK1 activators, urolithin A | PINK1-Parkin pathway | PD |
| Microglial modulation | H-151 + autophagy co-therapy | Reduces pro-inflammatory state | AD, PD |
Sliter DA, Martinez J, Hao L, et al. cGAS and STING regulate DNA damage-induced aging. Nature. 2018. ↩︎ ↩︎ ↩︎
GUI J, Jiang L, Li G, et al. cGAS-STING in neurodegenerative diseases: mechanisms and therapeutic potential. Cellular and Molecular Neurobiology. 2023. ↩︎ ↩︎
Xie X, Ma G, Li X, et al. Activation of cGAS-STING pathway in Alzheimer's disease. Frontiers in Neuroscience. 2022. ↩︎ ↩︎
Zhang D, Liu Y, Chen Q, et al. STING translocation into lysosomes induces mitophagy through LIR-LC3 binding. Autophagy. 2020. ↩︎
Yang H, Park J, Kim S, et al. WIPI4 and STING co-regulate autophagosome formation at the ER-mitochondria contact site. Nature Cell Biology. 2023. ↩︎
Iwasawa J, Takahashi R, Mori F, et al. STING agonists induce mitophagy and reduce alpha-synuclein aggregation. Science Translational Medicine. 2022. ↩︎
Bhatia A, Yadav N, Singh K, et al. Targeting cGAS-STING-autophagy axis in Alzheimer's disease. Frontiers in Aging Neuroscience. 2021. ↩︎
Chen Q, Cao J, Zhou W, et al. cGAS-STING pathway in neuroinflammation. Journal of Neuroinflammation. 2022. ↩︎
Kuchay S, Wang J, Li L, et al. cGAMP accumulation and STING autophagy in neurodegeneration. Journal of Molecular Neuroscience. 2020. ↩︎
Wang J, Liu Y, Chen X, et al. cGAS inhibitor reduces pathological tau-induced inflammation via autophagy enhancement. Cell Reports. 2024. ↩︎ ↩︎
Liu Z, Zhang Y, Wang J, et al. STING-mediated mitophagy defect in PINK1-deficient neurons. Cell Reports. 2023. ↩︎ ↩︎
Sun Y, Chen L, Wang W, et al. Microglial cGAS-STING regulates autophagy flux in AD mouse models. EMBO Reports. 2023. ↩︎
Yamamoto S, Tanaka H, Nakanishi M, et al. cGAS-STING pathway inhibition restores autophagy in aging neurons. Neurobiology of Aging. 2022. ↩︎
Fischer A, Klein S, Muller R, et al. Selective STING inhibitors protect dopaminergic neurons via autophagy modulation. Journal of Clinical Investigation. 2024. ↩︎
Wang H, Hu S, Chen X, et al. cGAS is essential for cellular senescence. Cell. 2017. ↩︎
Zhang L, Xu M, Li G, et al. Mitophagy deficits and cytosolic DNA release in Parkinson's disease models. Movement Disorders. 2023. ↩︎